CST, 13520S, Spartin Antibody

Polyclonal Antibody for studying SPG20. Validated for Western Blotting. Highly specific and rigorously validated in-house, Spartin Antibody (CST #13520) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity Spartin Antibody recognizes endogenous levels of total spartin protein. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human spartin protein. Antibodies are purified by protein A and peptide affinity chromatography. Background Spastic paraplegia 20 (spartin) is encoded by the gene in humans, which is altered in some individuals with an autosomal recessive form of hereditary spastic paraplegia known as Troyer syndrome (1,2). While Troyer syndrome research studies have yet to clearly describe the subcellular localization or function of spartin, additional work implicates spartin in endosomal trafficking, microtubule dynamics, and lipid homoeostasis (3-5). This multifunctional protein is ubiquitously expressed within the nervous system and in non-neuronal tissues, and displays a diverse pattern of cellular localization (6). The gene promoter is hypermethylated in many cases of colorectal cancer, which results in decreased spartin expression and cytokinesis arrest. This suggests that spartin expression and methylation state could be a promising biomarker for colorectal tumors (7). Alternate Names KIAA0610; SPART; Spartin; spastic paraplegia 20 (Troyer syndrome); Spastic paraplegia 20 protein; SPG20; TAHCCP1; Trans-activated by hepatitis C virus core protein 1 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 78 SOURCE: Rabbit